Summary & Overview
HCPCS C9175: Injection, treosulfan, 50 mg
HCPCS Level II code C9175 designates a 50 mg unit of treosulfan administered by injection for antineoplastic therapy. As a drug-specific HCPCS Level II code, C9175 is used on claims to identify treosulfan supplies delivered for systemic cancer treatment and to support billing for infusion services. Nationally, accurate use of HCPCS drug codes affects reimbursement, inventory tracking, and clinical documentation for oncology care.
Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of coverage and billing considerations across major public and commercial payers, typical service settings for administration, and clinical context for treosulfan as an injectable chemotherapy agent. The publication also summarizes common claim modifiers and billing practices observed for HCPCS drug coding, benchmarks for reimbursement where available, and policy updates relevant to HCPCS drug codes.
This resource is intended for billing managers, revenue cycle staff, oncology clinicians, and policy professionals seeking a national-level reference on coding and claim submission for treosulfan injections using HCPCS Level II code C9175.
Billing Code Overview
HCPCS Level II code C9175 represents Injection, treosulfan, 50 mg. This code describes a parenteral chemotherapy agent supplied in 50 mg increments for systemic oncologic treatment. The service type is injectable chemotherapy/antineoplastic therapy, and the typical site of service is hospital outpatient infusion center, oncology clinic, or ambulatory infusion center where intravenous or parenteral chemotherapy is administered.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with hematologic malignancy undergoing conditioning chemotherapy prior to hematopoietic stem cell transplantation or receiving treosulfan as part of a myeloablative or reduced-intensity conditioning regimen. The patient presents to an outpatient infusion center or inpatient oncology unit for administration. The workflow includes pre-infusion assessment (vital signs, labs for organ function and counts), verification of chemotherapy orders and dose (treosulfan dosed in mg/kg; C9175 represents the product treosulfan, 50 mg), preparation by pharmacy under sterile technique, appropriate chemotherapy safety checks and consent confirmation, placement of peripheral IV or central venous access, antiemetic and hydration orders as indicated, administration of treosulfan via intravenous infusion over the prescribed timeframe, monitoring for infusion reactions and cytopenia-related complications, post-infusion documentation of dose administered or reason for dose modification, and coordination of subsequent transplant or supportive care planning.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
52 | Reduced services | Use when less than full dose or partial administration of the chemotherapy product occurred intentionally, e.g., dose reduction during infusion with documentation. |